COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
November 02, 2023 07:00 ET
|
COMPASS Pathways
Highlights: COMP360 Phase 3 pivotal program ongoing with expanding European clinical sitesSecured up to $285 million private placement financing with $125 million upfrontCash position at September 30,...
COMPASS Pathways announces CFO transition
October 26, 2023 08:00 ET
|
COMPASS Pathways
LONDON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS” or the “company”), a biotechnology company dedicated to accelerating patient access to evidence-based...
COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results on November 2, 2023
October 24, 2023 16:01 ET
|
COMPASS Pathways
LONDON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways appoints Daphne Karydas to its Board of Directors
September 18, 2023 16:31 ET
|
COMPASS Pathways
LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression
September 06, 2023 04:00 ET
|
COMPASS Pathways
LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
COMPASS Pathways to participate in upcoming September investor conferences
August 29, 2023 16:30 ET
|
COMPASS Pathways
LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors
August 16, 2023 08:58 ET
|
COMPASS Pathways
Transaction led by healthcare specialist investors, TCGX and Aisling Capital $125 million financing upfront with up to an additional $160 million tied to exercise of warrants Net proceeds...
COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights
August 03, 2023 07:00 ET
|
COMPASS Pathways
LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Highlights: COMP360 Phase 3 pivotal program ongoing and on trackCPT® III code for in-person psychedelic therapy support accepted by the American Medical...
COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023
July 31, 2023 08:32 ET
|
COMPASS Pathways
LONDON, July 31, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine
July 25, 2023 04:00 ET
|
COMPASS Pathways
LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...